Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]
Discontinued
Reference number: GID-TA10906
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer have been revised. It is anticipated that the appraisal will begin in late-August 2023 when we will write to you about how you can get involved.